Hematopoiesis News Volume 13.27 | July 5 2022

    By
    lbeveridge
    -
    0
    23








    2022-07-05 | HN 10.26


    Hematopoiesis News by STEMCELL Technologies
    Vol. 10.26 – 15 July, 2022
    TOP STORY

    STAT1 Is Essential for HSC Function and Maintains MHCIIhi Stem Cells that Resists Myeloablation and Neoplastic Expansion

    Investigators showed that loss of STAT1 altered the steady state hematopoietic stem/progenitor cell landscape, impaired HSC function in transplantation assays, delayed blood cell regeneration following myeloablation, and disrupted molecular programs which protect HSCs including control of quiescence.
    [Blood]

    Abstract
    Subscribe to our immunology newsletters for a chance to win a personalized lab coat
    PUBLICATIONSRanked by the impact factor of the journal

    The Splicing Factor RBM17 Drives Leukemic Stem Cell Maintenance by Evading Nonsense-Mediated Decay of Pro-Leukemic Factors

    Scientists demonstratef that upregulation of the splicing factor, RBM17 preferentially marked and sustained leukemic stem cells and directly correlated with shorten patient survival.
    [Nature Communications]

    Full Article

    Degradation of GSPT1 Causes TP53-Independent Cell Death in Leukemia whilst Sparing Normal Hematopoietic Stem Cells

    The authors identified the domains of GSPT1 essential for cell survival and showed that GSPT1 degradation leads to impaired translation termination, activation of the integrated stress response pathway, and TP53-independent cell death.
    [Journal of Clinical Investigation]

    AbstractFull ArticleGraphical Abstract

    Combination Elotuzumab and Lenalidomide Treatment Efficacy Is Dependent on Crosstalk between NK Cells, Monocytes and Myeloma Cells

    Researchers used a humanized myeloma mouse model and adoptive transfer of human NK cells to show that elotuzumab and lenalidomide treatment controlled myeloma growth, and this was mediated through CD16 on NK cells.
    [Haematologica]

    Abstract

    Epigenetic Modifier SMCHD1 Maintains a Normal Pool of Long-Term Hematopoietic Stem Cells

    Structural maintenance of chromosomes hinge domain containing 1 (Smchd1)-deleted mice maintained steady-state hematopoiesis despite showing impaired reconstitution capacity in competitive bone marrow transplantations and age-related hematopoietic stem cell loss.
    [iScience]

    AbstractGraphical Abstract

    High Yield Secretion of Human Erythropoietin from Tobacco Cells for Ex Vivo Differentiation of Hematopoietic Stem Cells towards Red Blood Cells

    To overcome the bottlenecks of low protein productivity and secretion, erythropoietin was expressed in tobacco BY-2 cells with a designer peptide tag, termed (SP)20 that consists of 20 tandem repeats of a “Ser-Pro” motif.
    [Journal of Biotechnology]

    Abstract

    Extramedullary Relapse of Acute Myeloid Leukemia in Brachial Plexus after Allogeneic Stem Cell Transplantation: A Case Report

    Scientists reported a case of extramedullary relapse of acute myeloid leukemia in the brachial plexus of a 41-year-old woman treated with allogeneic hematopoietic stem cell transplantation.
    [BMC Neurology]

    Full Article

    Comparison of Autologous and Allogeneic Hematopoietic Cell Transplantation Strategies in Patients with Primary Plasma Cell Leukemia, with Dynamic Prediction Modeling

    Researchers undertook a retrospective analysis from 1998-2014 of 751 patients with primary plasma cell leukaemi undergoing one of four transplant strategies; single autologous transplant, single allogeneic transplant or a combined tandem transplant either auto-allo or auto-auto.
    [Haematologica]

    Abstract

    Impact on Outcomes of Mixed Chimerism of Bone Marrow CD34+ Sorted Cells after Matched or Haploidentical Allogeneic Stem Cell Transplantation for Myeloid Malignancies

    An investigation of donor/recipient chimerism in the population of bone CD34+ sorted cells was performed in 261 allogeneic hematopoietic stem cell transplantation recipients with myeloid malignancies.
    [Bone Marrow Transplantation]

    Abstract

    Allogeneic Hematopoietic Cell Transplantation in Patients with a Hematologic Malignancy and a Prior History of Breast Cancer

    Transplant outcomes were compared to 289 control patients without a history of breast cancer from the same time period. Main outcomes included survival, disease-free survival, non-relapse mortality, relapse or progression of hematologic malignancy, and incidence of recurrent breast cancer after hematopoietic cell transplantation.
    [Breast Cancer Research and Treatment]

    Abstract
    ON1099-728 x 90
    REVIEWS

    Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations

    Mutations in the genes encoding erythropoietin (EPO), EPO receptor, HIF-2α, prolyl hydroxylase domain protein 2, or von Hippel–Lindau protein caused familial erythrocytosis.
    [Annual Review of Medicine]

    Abstract
    INDUSTRY AND POLICY NEWS

    Kite’s CAR T-Cell Therapy Yescarta®. Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma

    Kite announced that the European Commission has approved its CAR T-cell therapy Yescarta® for the treatment of adult patients with relapsed or refractory follicular lymphomaafter three or more lines of systemic therapy.
    [Kite]

    Press Release

    Genmab to Submit Biologics License Application to US Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B Cell Lymphoma (LBCL)

    Genmab A/S announced its intent to submit a biologics license application to the FDA for subcutaneous epcoritamab, an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma.
    [Genmab A/S]

    Press Release
    FEATURED EVENT

    EHA Research Conference 2022

    October 17 – October 20
    Palermo (Sicily), Italy

    > See All Events

    JOB OPPORTUNITIES

    Clinical Cell Therapy Associate – Cord Blood Bank

    University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Postdoctoral Scientist – Cardiovascular Magnetic

    Boston Children’s Hospital – Boston, Massachusetts , United States

    Postdoctoral Fellow Positions – Translational Research

    University of Maryland School of Medicine – Baltimore, Maryland, United States

    Scientific Editor – Blood Cancer Discovery

    American Association for Cancer Research – Various, United States

    Postdoctoral Training Fellow – Applied Biotechnology

    Francis Crick Institute – London, England, United Kingdom

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter